

North Central Cancer Treatment Group

N0272 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) In Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

Status Change – November 22, 2005

**NOTICE OF STATUS CHANGE**

Study 1, Arm C (EAC's patients) has met patient accrual for dose level 1. Therefore Study 1, Arm C (EAC's patients) is temporarily suspended to patient accrual effective immediately, November 22, 2005. Patient entry will not be permitted until further notification is issued.

**Please retain this notice with the protocol.**